Fig. 2From: Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysisForest plot of HR of PFS (a) and OS (b) associated with pazopanib versus sunitinibBack to article page